Director Duncan Moore of GH Research PLC filed a Form 4 on August 13, 2026, disclosing the acquisition of 2,202 share options in the company on August 11, 2026.
Key Highlights
- Reporting person: Duncan Moore, serving as a Director of GH Research PLC (NASDAQ:GHRS)
- Transaction date: August 11, 2026, with the form filed August 13, 2026
- Securities acquired: 2,202 Share Options (Right to Buy) with an exercise price of $0.025 per share
- Vesting status: The options are immediately fully vested but are not exercisable until August 11, 2028
- Expiration date: August 11, 2033
- Post-transaction holdings: 2,202 derivative securities beneficially owned directly, at a price of $0 for the derivative security itself
Duncan Moore's Option Grant Details at GH Research PLC
According to the filing, Duncan Moore, a Director at GH Research PLC (NASDAQ:GHRS), acquired 2,202 Share Options (Right to Buy) on August 11, 2026, through a transaction coded "A" (acquired). The exercise price of the derivative security is $0.025, and the underlying securities are ordinary shares of GH Research PLC. The filing indicates the price of the derivative security itself was $0.
The filing discloses that the share options are immediately fully vested, but are "not exercisable until August 11, 2028," per the explanation of responses included in the document. The options are set to expire on August 11, 2033, giving Moore a window to exercise between August 11, 2028 and August 11, 2033. Following the reported transaction, Moore beneficially owns 2,202 derivative securities directly, with no non-derivative securities reported in Table I of the filing.
Moore's address is listed as c/o GH Research PLC, Joshua Dawson House, Dawson Street, Dublin, Ireland. The Form 4 was signed by Duncan Moore and dated August 13, 2026. No amendment date was indicated, suggesting this is an original filing. The filing was made pursuant to Section 16(a) of the Securities Exchange Act of 1934.
What Was Disclosed
The filing reports that Director Duncan Moore acquired 2,202 immediately vested but not yet exercisable share options in GH Research PLC on August 11, 2026, at an exercise price of $0.025, expiring August 11, 2033.






Please wait processing your request...